Drug class
Small Interfering RNA; Transthyretin-directed RNA Interaction
Mechanism of action
Vutrisiran is a double-stranded siRNA-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.
General use cases
- Polyneuropathies
- Amyloid Neuropathies, Familial
- the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults
- the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
